Moldco

MoldCo is a healthcare technology company operating a virtual care platform focused on illness associated with mold exposure, including chronic inflammatory response syndrome (CIRS). Patients begin with an online intake that scores mold risk against more than 100 datapoints covering 12 symptoms and 8 body systems, described by the company as built on 30 years of research. Those who qualify are matched with a provider who directs a three-phase prescription protocol — detox (a binder), clear (a nasal spray) and repair (a peptide) — delivered to the patient's home, with ongoing check-ins and plan adjustments managed through the MoldCo app.

Alongside care, the company sells testing: clinical lab panels measuring markers such as TGF-β1, MMP-9 and MSH, and at-home kits that assess whether mold is present in a patient's residence. MoldCo states that it is not a laboratory or medical provider; clinical services are furnished by a network of independent providers, including an affiliated clinical practice, Immune Co Medical Group P.A., together with third-party licensed clinicians, participating pharmacies and CLIA-certified laboratories. The site notes that health claims have not been evaluated by the FDA and that results vary.